Jan 27, 2023 by James Halley3 Healthcare Stocks to Buy and Hold for the Next 10 YearsThese companies have the therapies to boost revenue for a decade.
Jan 26, 2023 by James HalleyWhy Shares of Editas Medicine Jumped This WeekIt's been a seesaw month for the clinical-stage gene-editing biotech.
Jan 26, 2023 by James HalleyWhy Shares of Zencor Rose This WeekThe clinical-stage biotech has seen its shares rise since a company presentation a few weeks ago.
Jan 25, 2023 by James Halley3 Cannabis Companies To Watch if Ohio Approves Adult-Use Cannabis SalesThe state has been overlooked in cannabis sales, but that won't last.
Jan 25, 2023 by James Halley3 Reasons to Buy AbbVie and 2 Reasons Not to BuyThe pharmaceutical specialist is facing a pivotal year in 2023, thanks to growing competition.
Jan 24, 2023 by James HalleyBetter Long-Term Buy in 2023: Exact Sciences or Veracyte?As cancer screenings are becoming covered more often, both companies stand to gain.
Jan 23, 2023 by James Halley3 Cannabis Stocks to Buy and Hold for the Next 10 YearsAll of these companies are trading at low price-to-book-value ratios.
Jan 23, 2023 by James HalleyThe Top Healthcare Stocks to Buy With $100Don't overlook these big-name foreign healthcare stocks.
Jan 22, 2023 by James HalleyBetter Biotech Buy: Bluebird Bio or CRISPR Therapeutics?Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.
Jan 22, 2023 by James Halley2 Stocks That Could Turn $100 Into $1,000 by 2028These growth stocks have substantial tailwinds.
Jan 21, 2023 by James HalleyIs Now a Good Time to Invest in a Medical REIT?Medical REITs, down for the past year, may be already in comeback mode.
Jan 20, 2023 by James HalleyWhy Evolus Shares Jumped This WeekThe company said it expects to turn a profit in the fourth quarter.
Jan 20, 2023 by James HalleyWhy Shares of Biomea Fusion Jumped This WeekThe company launched its second trial this year for its lead therapy.
Jan 20, 2023 by James HalleyWhy Shares of Scilex Soared This WeekImproved revenue estimates and buyout rumors have been driving the stock higher.
Jan 19, 2023 by James HalleyWhy Shares of Vaxxinity Jumped This WeekInvestors are hoping the company's COVID-19 vaccine will turn the company from a clinical-stage biotech to a commercial one.
Jan 19, 2023 by James Halley2 Cannabis Stocks to Buy and 1 to Avoid in 2023The three are among the largest cannabis multi-state operators in the U.S.
Jan 18, 2023 by James Halley3 Biotech Stocks Under $15 Worth a Second Look in 2023All three stocks have promising therapies that could drive revenue in the coming years.
Jan 14, 2023 by James HalleyBetter Healthcare Buy for 2023: Medpace Holdings or Doximity?The healthcare stocks expect similar revenue growth in 2023.
Jan 14, 2023 by James Halley3 Growth Stocks Poised for Huge Gains in 2023These big pharmaceuticals are poised for back-to-back big years.
